Anti-ferritin polyclonal antibody
Alternative Names: Ferritarg P; Ferritarg-P - MABLifeLatest Information Update: 18 Sep 2015
Price :
$50 *
At a glance
- Originator MAT Biopharma
- Developer MABLife
- Class Antineoplastics; Polyclonal antibodies; Radiopharmaceuticals
- Mechanism of Action Iron-binding protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hodgkin's disease
Most Recent Events
- 18 Sep 2015 No recent reports on development identified - Phase-I/II for Hodgkin's disease in France (IV)
- 29 Jul 2011 MAT Biopharma has been renamed as MABLife
- 22 Feb 2011 Ferritarg® is still in phase I/II development for refractory Hodgkin's lymphoma in France